[go: up one dir, main page]

LT3658552T - N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido - Google Patents

N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido

Info

Publication number
LT3658552T
LT3658552T LTEPPCT/KR2018/008379T LTKR2018008379T LT3658552T LT 3658552 T LT3658552 T LT 3658552T LT KR2018008379 T LTKR2018008379 T LT KR2018008379T LT 3658552 T LT3658552 T LT 3658552T
Authority
LT
Lithuania
Prior art keywords
morpholinophenyl
pyrazol
pyrimidin
dimethylamino
methoxy
Prior art date
Application number
LTEPPCT/KR2018/008379T
Other languages
English (en)
Inventor
Sang-Ho Oh
Ja-Heouk Khoo
Jong-Chul Lim
Seong-Ran LEE
Hyun Ju
Woo-Seob Shin
Dae-Gyu Park
Su-Min Park
Yoon-Ah HWANG
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3658552(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of LT3658552T publication Critical patent/LT3658552T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
LTEPPCT/KR2018/008379T 2017-07-28 2018-07-25 N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido LT3658552T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
LT3658552T true LT3658552T (lt) 2023-11-27

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/KR2018/008379T LT3658552T (lt) 2017-07-28 2018-07-25 N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido

Country Status (32)

Country Link
US (4) US10889578B2 (lt)
EP (1) EP3658552B1 (lt)
JP (2) JP7228562B2 (lt)
KR (1) KR102688084B1 (lt)
CN (2) CN116987112B (lt)
AU (2) AU2018308038B2 (lt)
BR (1) BR112020001278A2 (lt)
CA (1) CA3070069C (lt)
CO (1) CO2020000374A2 (lt)
DK (1) DK3658552T3 (lt)
EA (1) EA202090383A1 (lt)
ES (1) ES2962961T3 (lt)
FI (1) FI3658552T3 (lt)
HR (1) HRP20231191T1 (lt)
HU (1) HUE063533T2 (lt)
IL (2) IL271973B (lt)
LT (1) LT3658552T (lt)
MA (1) MA49700B1 (lt)
MD (1) MD3658552T2 (lt)
MX (2) MX2022008743A (lt)
MY (1) MY198379A (lt)
PH (1) PH12020500059A1 (lt)
PL (1) PL3658552T3 (lt)
PT (1) PT3658552T (lt)
RS (1) RS64654B1 (lt)
SA (2) SA522431428B1 (lt)
SG (1) SG11201913517UA (lt)
SI (1) SI3658552T1 (lt)
SM (1) SMT202300339T1 (lt)
UA (1) UA125317C2 (lt)
WO (1) WO2019022485A1 (lt)
ZA (1) ZA202001250B (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008743A (es) * 2017-07-28 2023-02-02 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina.
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CN116199701A (zh) * 2023-02-27 2023-06-02 安徽中医药大学 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
BR0214485A (pt) 2001-11-27 2004-09-14 Wyeth Corp 3-cianoquinolinas como inibidores de egf-r e her2 quinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
EP2684874B1 (en) 2006-10-23 2017-05-17 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
MX382352B (es) * 2008-06-27 2025-03-13 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos.
KR20120114224A (ko) 2009-10-12 2012-10-16 마이렉시스 인코포레이티드 Ｉｋｋ 엡실론 및/또는 ｔｂｋ１의 억제제로서의 아미노-피리미딘 화합물
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RS54070B1 (sr) 2010-12-13 2015-10-30 Array Biopharma Inc. SUPSTITUISANA N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDNA JEDINJENJA KAO INHIBITORI TIPA III RECEPTORA TIROZIN KINAZE
LT3333161T (lt) * 2011-07-27 2020-05-11 Astrazeneca Ab 2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
WO2013096637A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR122019019582B1 (pt) 2011-12-30 2021-07-13 Hanmi Pharm. Co., Ltd. Compostos derivados de tieno[3,2-d]pirimidina, composição farmacêutica contendo os ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
PT3929190T (pt) 2014-10-13 2025-02-19 Yuhan Corp Compostos e composições para modular atividades da cinase do mutante de egfr
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
MX2022008743A (es) * 2017-07-28 2023-02-02 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina.
DK3658547T3 (da) * 2017-07-28 2023-10-16 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
MA49703A (fr) 2017-07-28 2021-04-21 Yuhan Corp Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
US20210269427A1 (en) 2021-09-02
US20230312545A1 (en) 2023-10-05
NZ761156A (en) 2024-01-26
DK3658552T3 (da) 2023-11-20
MD3658552T2 (ro) 2024-02-29
CO2020000374A2 (es) 2020-05-05
SMT202300339T1 (it) 2023-11-13
EP3658552A1 (en) 2020-06-03
PT3658552T (pt) 2023-11-03
SA520411112B1 (ar) 2022-02-21
JP7539451B2 (ja) 2024-08-23
WO2019022485A1 (en) 2019-01-31
ES2962961T3 (es) 2024-03-22
HRP20231191T1 (hr) 2024-02-02
SA522431428B1 (ar) 2024-10-21
AU2022202936A1 (en) 2022-05-26
KR102688084B1 (ko) 2024-07-24
PL3658552T3 (pl) 2024-02-19
EP3658552A4 (en) 2021-06-23
MX393995B (es) 2025-03-24
UA125317C2 (uk) 2022-02-16
CN116987112A (zh) 2023-11-03
EP3658552B1 (en) 2023-09-13
US12187714B2 (en) 2025-01-07
MX2022008743A (es) 2023-02-02
JP2020528440A (ja) 2020-09-24
AU2018308038B2 (en) 2022-02-03
AU2018308038A1 (en) 2020-01-30
IL292429B1 (en) 2023-05-01
US20220281861A1 (en) 2022-09-08
MA49700A (fr) 2021-03-17
MA49700B1 (fr) 2023-09-27
CA3070069C (en) 2024-02-20
FI3658552T3 (fi) 2023-11-16
HUE063533T2 (hu) 2024-01-28
IL292429B2 (en) 2023-09-01
JP7228562B2 (ja) 2023-02-24
US11286253B2 (en) 2022-03-29
US11708362B2 (en) 2023-07-25
AU2022202936B2 (en) 2023-04-27
CN116987112B (zh) 2025-12-19
BR112020001278A2 (pt) 2020-07-21
SI3658552T1 (sl) 2023-11-30
US10889578B2 (en) 2021-01-12
JP2023027091A (ja) 2023-03-01
PH12020500059A1 (en) 2020-09-28
IL271973B (en) 2022-08-01
EA202090383A1 (ru) 2020-06-15
KR20190013553A (ko) 2019-02-11
IL271973A (en) 2020-02-27
SG11201913517UA (en) 2020-02-27
CN111315742A (zh) 2020-06-19
RS64654B1 (sr) 2023-10-31
IL292429A (en) 2022-06-01
CN111315742B (zh) 2023-09-01
US20200165236A1 (en) 2020-05-28
ZA202001250B (en) 2023-04-26
CA3070069A1 (en) 2019-01-31
MY198379A (en) 2023-08-28

Similar Documents

Publication Publication Date Title
LT3658552T (lt) N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido
IL285702A (en) Heterocyclic amides useful as protein modulators
EP3632907C0 (en) N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
LT3555070T (lt) Aminu pakeisti heterocikliniai junginiai, kaip ehmt2 inhibitoriai, ir jų panaudojimo būdai
EP3497086A4 (en) AMINOPYRIMIDINE SSAO INHIBITORS
LT3442947T (lt) Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai
DK3154950T3 (da) N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
DK3463351T3 (da) Behandling til parkinsons sygdom
EP3952876A4 (en) HETEROCYCLIC COMPOUNDS AND THEIR USES
DK3585324T3 (da) Sæt til neglekorrektion
DK3621948T3 (da) Amino(meth)acrylater
HUE058153T2 (hu) Amid vegyületek és ezek alkalmazása
EP3166961C0 (en) N-(HYDROPHOBIC-SUBSTITUTED) VANCOSAMYCIN-[PSI[C(=NH)NH]TPG4]-VANCOMYCIN AND [PSI[CH2NH]TPG4]-VANCOMYCIN
EP3582765A4 (en) MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF
EP3952879A4 (en) HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3952878A4 (en) HETEROCYCLIC COMPOUNDS AND THEIR USES
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
EP3414225C0 (en) CRYSTAL MODIFICATIONS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL) GUANIDINE HYDROCHLORIDE AND SALTS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL) GUANIDINE
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
EP3867243C0 (en) NOVEL N-(ISOPROPYL-TRIAZOLYL)PYRIDINYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AND THEIR USE
HUE046959T2 (hu) Eljárás N-(3,5-dimetilfenil)-N'-(2-trifluormetilfenil) guanidin elõállítására